60results about How to "Exert anti-tumor effect" patented technology

The invention discloses novel N-4-phenylsulfonamido--N'-1-desoxy-(2-desoxy-2-substituted-amino)-beta-D-glucopyransoylthiocarbamide compounds with the general formula disclosed in the specification, which have the activity of inhibiting carbonic anhydrase and further achieve the effect of resisting tumor metastasis and invasion. The compounds structurally have the three active segments sulfamine, substituted glucosamine and thiocarbamide, and the three active segments and Zn<2+> ions in the carbonic anhydrase form coordinate bonds, thereby inhibiting the catalytic activity of the enzyme and performing the function of resisting tumor metastasis and invasion. Thus, the compounds have application potential in the aspect of antitumor drugs. In the general formula, R is defined in the specification.

The invention discloses a TAT-IL-24-KDEL fusion protein which is a fusion protein of which TAT cell-penetrating peptide and endoplasmic reticulum positioning signal peptide KDEL are respectively connected with the N terminal and C terminal of interleukin-24(IL-24). The preparation steps comprises: performing PCR (Polymerase Chain Reaction) amplification to obtain a TAT-IL-24-KDEL encoding gene, by using pET28-SUMO as a carrier, converting BL21(DE3), and heterologously expressing the TAT-IL-24-KDEL fusion protein with SUMO label. Because the fusion protein is expressed in a mode of inclusion body, and a high-purity TAT-IL-24-KDEL fusion protein is obtained after the operations of renaturation, nickel column purification and label removing. The TAT-IL-24-KDEL fusion protein purified through flow cell experiment detection has apoptosis-promoting action to breast cancer MCF-7 cells, and the positioning condition of the fusion protein in the cells is detected by using immunofluorescence experiment detection. The invention firstly provides a preparation method of the TAT-IL-24-KDEL fusion protein; the purity reaches 92 percent; the TAT-IL-24-KDEL fusion protein can be effectively positioned on endoplasmic reticulum to promote the apoptosis of the breast cancer MCF-7 cells.

The invention discloses an in vitro expansion method for anti-tumor T cells from non-sentinel lymph nodes. The method comprises the following four steps: antigen-pulsed and immunosuppression blocking,T cell subset separation and excitated proliferation, reexcitation and rapid proliferation of a T cell subset, and harvesting. The in vitro expansion method has the characteristics that the activation of T cell specificity is facilitated, the anti-tumor capacity of T cells can be improved, the quantity of tumor specific T cells is increased, the operation is simple and convenient and the method is easy for popularization.

The invention relates to a bionic magnetosome loaded with siRNA and a preparation method of the magnetosome, and belongs to the field of chemistry and biomedicine. According to the bionic magnetosome, water-soluble MNC serves as the kernel and is wrapped by a white cell membrane, and siRNA is loaded between the MNC and the white cell membrane; antibodies or peptides with modifying groups can be coupled outside the white cell membrane of the bionic magnetosome in a covalence mode. By preparing MNC, M and MNC:siRNA and mixing an MNC:siRNA solution, an M solution and a buffer solution, the bionic magnetosome is obtained; the white cell membrane of the bionic magnetosome is modified by the peptides or antibodies through the modifying groups, and the bionic magnetosome coupled with the antibodies or peptides is obtained. The MNC in the bionic magnetosome has positive charges, can adsorb siRNA and is wrapped by M for bionics, a focus is reached efficiently and rapidly, and meanwhile immune elimination of organisms is avoided.

The invention provides an application of miR-124-3p and analogues thereof in preparation of anti-breast cancer disease drugs. The miR-124-3p has a sequence of 5'-UAAGGCACGCGGUGAAUGCCAA-3'. Experiments prove that the expression of the miR-124-3p is significantly inhibited during the occurrence of breast cancer; with restoring of the expression of the miR-124-3p, the proliferation and migration of breast cancer cells can be inhibited by targeting adjustment of the expression of MGAT5, and thus an anti-tumor role is played. A new molecular marker is provided for diagnosis of breast cancer and a new potential molecular target is provided for clinical treatment.

The invention discloses a nanoparticle compound with tumor microenvironment responsive deformation. The nanoparticle compound is formed by combining an amphiphilic oligo-polypeptide drug conjugate andbeta-carboxylic acid amide polylysine through electrostatic interaction. The amphiphilic oligo-polypeptide drug conjugate is a product obtained by condensation of an anti-cancer drug adriamycin and an oligo-polypeptide KIGLFRWR through a chemical bond. The nanoparticle compound can be passively gathered at a tumor site in a targeted manner; under the acidic pH condition of a tumor region, a beta-carboxylic acid amide group connected to polylysine is broken, charge of the polylysine is changed into positive charge from negative charge, and the polylysine repels the amphiphilic oligo-polypeptide drug conjugate with positive charge, so that the nanoparticle compound is dissociated; and then the amphiphilic oligo-polypeptide drug conjugate can be further assembled into a long fiber, so that long-time retention is achieved at the tumor site, the drug adriamycin is slowly released, and the efficient anti-cancer effect is achieved.

The invention relates to a preparation method of an oyster shell extract. The method comprises the following steps of: adding water-containing solution of alcohol into oyster shell powder in a material to liquid ratio of 1g:2-20mL, performing reflux extraction and filtering or centrifugally separating liquid out; and concentrating the obtained liquid under reduced pressure, extracting with an organic solvent, separating an organic solvent layer out, concentrating under reduced pressure and drying to obtain the oyster shell extract. Tests by a lissamine rhodamine B method indicate that the prepared oyster shell extract has the function of inhibiting cell proliferation of a plurality of tumor cell strains; and tests by a methyl thiazolyl tetrazolium method indicate that the oyster shell extract has the function of inhibiting cell proliferation of human umbilical vein endothelial cells. Experiments indicate that the oyster shell extract can play a role in resisting tumors by inhibiting tumor cell proliferation and angiogenesis. Therefore, the oyster shell extract of the invention can be taken as a cell proliferation inhibitor, an angiogenesis inhibitor and an anti-tumor agent.

The invention relates to a medicinal preparation and a preparation method thereof and in particular relates to a compound Chinese medicament for treating cancer and a preparation method thereof. The compound Chinese medicament for treating cancer is produced into spray and aerosol, the sprayed mist-state liquid is mixed with negative oxygen ions to both act on the nasal cavity, or directly produced into oral solution. The medicament is prepared from fermentative cordycep fungal powder and ganoderma lucidum powder at a weight ratio of 1:(0.8-1.2). The preparation method comprises the following steps: weighing the fermentative cordycep fungal powder and ganoderma lucidum powder according to the weight ratio; sealing with deionized water and heating to 80-100 DEG C, extracting for 1 hour, and filtering to obtain an extract; sealing with deionized water and heating to 80-100 DEG C, filtering to obtain an extract; combining the two extracts, heating to 80 DEG C, concentrating into a medicinal concentrated solution; and cooling to normal temperature to prepare the medicinal concentrated solution of the compound Chinese medicament for treating cancer.

The invention relates to a high-penetrability tumor target lipid insert and a preparation method thereof. The insert is prepared from a high-penetrability peptide iRGD containing ingredient and DSPE-PEG-MAL, and can be inserted onto a plurality of drug-loaded systems and cells to realize active tumor target. According to the preparation method, the substance of the high-penetrability peptide iRGD containing ingredient serving as a molecule for realizing tumor active target and high penetrability is used for modifying a segment of lipid molecules to form a multi-functional tumor target insert capable of definitely reinforcing tumor target. Repeated experiments after successful construction verify that the tumor target lipid insert has definite tumor targeting and can be used for actually reinforcing tumor local aggregation of cell and cell membrane preparations and improving the anti-tumor treatment effect.

The invention provides an application of ART (artesunate) as an anti-leukemia-tumor drug and relates to the field of medical health. ART is taken as a chemotherapeutic drug with targeted inhibition of STAT3 for leukemia tumor. Expression level of STAT3 can be inhibited rapidly and effectively, so that leukemia treatment is realized, ART has a strong inhibition effect on THP-1 cell proliferation and can induce THP-1 apoptosis, and the fact that ART can remarkably reduce protein level of STAT3 and activate Caspase8 and Caspase3 protein simultaneously to induce apoptosis is further proved. Intraperitoneal injection of ART into a THP-1 cell transplantation tumor mouse model discovers that ART can obviously inhibit tumor growth and down-regulate the expression level of STAT3 in tumor tissue. Experiments prove that ART plays an anti-tumor effect on THP-1 by down-regulating expression of STAT3 and activating apoptotic proteins Caspase8 and Caspase3 simultaneously.

The invention relates to a macrophage drug-loading preparation and a preparation method thereof. The preparation method for the macrophage drug-loading preparation comprises the following steps: (1) enabling an anti-tumor drug to be dissolved in a solvent, and preparing an anti-tumor drug solution; (2) enabling macrophages to be suspended in a glucose solution of which a mass percent is (5+/-1)%,to obtain macrophage suspension; (3) adding the anti-tumor drug solution to the macrophage suspension, and uniformly mixing; and (4) after culturing for 1.5-3.5 hours, centrifuging, and collecting a cell precipitate, to obtain the macrophage drug-loading preparation. The macrophage drug-loading preparation is high in encapsulation efficiency, long in drug-loading cell activity duration time, capable of slowly releasing a drug, and has good tumor targeting and inhibiting effects.

The invention discloses MicroRNA (micro ribonucleic acid) for regulating gene expression of B7-H4 (a molecule of the B7 family). The microRNA is nucleic acid, functional segment or variant including a sequence of 5'-UGAGAUGAAGCACUGUAGCUC-3'. The microRNA is miR-143. Performed in-vitro biological function tests show that hsa-miR-143 is capable of inhibiting molecular expression of the B7-H4 by bonding with 3'-UTR (untranslated regions) of the B7-H4 gene, and antitumor effect is achieved by regulating a signal path of the B7-H4 and/or expression and functions of the miR-143.

The invention provides composition having an immunoregulatory activity, as well as a preparation and an application thereof. The composition comprises an active ingredient and optional auxiliary materials, and is characterized in that the active ingredient comprises seaweed or defatted seaweed and oyster shells or comprises an extract from extraction of the seaweed or defatted seaweed and the oyster shells. The seaweed and oyster shell composition has the technical effect of synergistic interaction on the effect of improving immunocompetence.

The invention discloses microRNA (micro ribonucleic acid) for regulating gene expression of PTEN (phosphatase and tensin homolog). The microRNA is nucleic acid, functional segment or variant including a sequence of 5'-caaagugcucauagugcagguag-3'. The microRNA is miR-20b. In-vitro biological function tests show that hsa-miR-20b is capable of inhibiting molecular expression of the PTEN by bonding with 3'-UTR (untranslated regions) of the PTEN gene, and antitumor effect can be achieved by regulating a signal path of the PTEN and/or expression and functions of the miR-20b.

The invention provides a liposome co-loaded with CD73 antibody and adriamycin, and a preparation method and application of the liposome. A lipid core coated with the adriamycin is arranged in the liposome co-loaded with the CD73 antibody and the adriamycin, the outside of the lipid core is modified with the CD73 antibody, and the CD73 antibody is coupled to a phospholipid PEG active ester micelle and then is modified on the surface of the lipid core. The lipidosome co-loaded with the CD73 antibody and the adriamycin reduces the drug resistance and the toxic and side effects of the adriamycin in treatment of the triple negative breast cancer, improves in-vivo biological distribution of the adriamycin, improves bioavailability, and turns an immune microenvironment in a triple negative breast cancer tumor, so that the triple negative breast cancer tumor is converted into a thermal tumor, and a relatively good treatment effect for the triple negative breast cancer is realized.

The invention relates to the technical field of biomedicine, and provides novel medical applications of miRNA miR-133, in particular to the applications of miR-133 in targeted therapy of malignant tumor molecules. The invention further discloses applications of miR-133 in preparing medicines for resisting gastric cancer. The experiment proves that during the generating process of gastric cancer, the expression of miR-133 is obviously inhibited; the recovery of the expression of miR-133 can be realized in the manner that the proliferation of gastric cancer cells is inhibited by targeted anti-apoptosis molecules Mcl-1 and Bcl-xL, so that the anti-tumor effect is achieved. With the adoption of the technical scheme, a novel potential molecular target is provided for the clinical treatment of gastric cancer.

The invention provides a preparation method of a class of flavone-ligustrazine series derivatives, and applications of the flavone-ligustrazine series derivatives in preparation of antitumor drugs. According to the invention, the compound has obvious inhibition activity on the growth of tumor cell lines (HepG-2, Bel-7402, MCF-7, HT-29 and Hela), and almost does not affect a human normal vascular endothelial cell (HUVEC-12) line, the antitumor activity of part of the compounds is similar to the antitumor activity of a positive drug cis-platinum; the compound CH-5 has high selectivity between tumors and between tumors and normal cell lines, and has the strongest inhibition effect on liver cancer (Bel-7402), wherein the IC50s of the compound to HepG-2, Bel-7402, HT-29, MCF-7 and Hela respectively are 17.31+/-0.47 [mu]M, 10.74+/-1.12 [mu]M, 31.88+/-1.96 [mu]M, 29.79+/-2.18 [mu]M and 25.11+/-1.80 [mu]M; and the compound CH-5 has no killing effect on HUVEC-12 cells while inhibiting cancer cells, and shows a certain proliferation promoting activity.

The invention discloses application of a thiourea molecule in preparation of antitumor drugs. The structural formula of the thiourea molecule is selected from formula I to formula IV, wherein R1, R2 and R3 are independently selected from hydrogen, alkyl with a carbon number of 1-10, aryl or a heteroatom group containing N, O and S. The invention provides new application of the thiourea molecule, specifically in preparation of anticancer drugs. The thiourea molecule is adopted as the anti-cancer drug, or is used as the active ingredient for preparation of pharmaceutical preparations, the antitumor drugs show very low cytotoxicity to human lung adenocarcinoma cells (A549), human breast cancer cells (BCap-37), human oral epidermoid carcinoma cells (KB), human lung fibroblast (HFL1) and human bronchial epithelial cells (BEAS-2B), but has very good antitumor effect at the animal level. (formula I, formula II, formula III, and formula IV).

The invention discloses a pharmaceutical betaine conjugate and a pharmaceutical composition and an application thereof. The pharmaceutical composition contains the pharmaceutical betaine conjugate or a pharmaceutic composition composed of the pharmaceutical betaine conjugate and a pharmacologically acceptable carrier and is made into liquid preparations, solid preparations, semi-solid preparations, capsules, granules, gels and injections. The pharmaceutical composition is of liposomal nano-particles made of the pharmaceutical betaine conjugate or the composition of the pharmaceutical betaine conjugate and auxiliaries, to be specific, 10-100nm in particle size. The pharmaceutical betaine conjugate and the liposomal nano-particles thereof can serve as the liquid preparations, the solid preparations, the semi-solid preparations, sterilization preparations and sterile preparations and are low in toxicity and applicable to various tumor efficient treatments.